Opus Genetics (IRD) Reiterated at Overweight by Cantor Fitzgerald on Positive Update

July 10, 2026 6:45 AM

Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $15.00 price target on Opus Genetics (NASDAQ: IRD).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found